🟢 BioCryst Pharmaceuticals is trading 4.8% up in pre-market with catalyst attribution unconfirmed

BioCryst Pharmaceuticals is trading 4.8% higher in pre-market at $8.49 on October 6, versus the October 5 close of $8.10; available sources do not confirm a catalyst for the gain.

• On October 5, the company announced a seven-member Scientific Advisory Board to guide research, development strategy, and pipeline expansion, with a focus on external innovation.
• Broader U.S. markets are higher, but supplied index moves are below 0.5%. No verified pre-market volume or activity details were found, limiting attribution confidence.